McKesson (MCK) Oncology & Multispecialty — Payments for Restructuring — Quarterly & Annual

Screener

Other segment segments

Medical-Surgical Solutions

$16M-68.0%

North American Pharmaceutical

$3M—

Prescription Technology Solutions

$0—

Similar metrics at other companies

PSK

PSKYStudios — Payments for Restructuring

$25M—

WKCAviation — Payments for Restructuring

$1.2M+500%

WKCLand — Payments for Restructuring

$8.3M+337%

WKCMarine — Payments for Restructuring

$900K—

MYPSplayAWARDS — Payments for Restructuring

$37K-80.3%

MYPSplayGAMES — Payments for Restructuring

$200K-90.2%

Other financials

Income statement

Revenue$105.38B+7.7%

Gross profit$3.7B+12.4%

Operating income$1.3B+27.3%

Net income$614.0M-21.7%

EPS (diluted)$5.15-17.6%

Balance sheet

Cash & equivalents$5.3B+95.9%

Total debt$13.0B+15.7%

Total equity-$4.2B-116%

Total assets$88.3B+8.6%

Cash flow

Operating cash flow-$220.0M+76.0%

CapEx$112.0M+0.9%

Free cash flow-$332.0M+67.7%

Valuation

Market cap$101.59B+15.6%

Enterprise value$109.31B+13.4%

P/E22.1×-5.7×

P/S0.3×0.0×

Profitability

Gross margin3.6%+0.1pp

Operating margin1.6%+0.4pp

Net margin1.1%+0.3pp

FCF margin1.6%0.0pp

Returns & leverage

Return on equity36%—

Debt / equity2×—

Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRestructuring.

The source filing: McKesson’s 10-K, filed May 8, 2026.

Filed: May 7, 2026, 8:00 PM EDT
Fiscal year: FY2026
Accession: 0000927653-26-000069

(In millions)	North American Pharmaceutical	Oncology & Multispecialty	Prescription Technology Solutions	Medical-Surgical Solutions	Corporate & Other	Total
Balance, March 31, 2024 (1)	$23	$3	$5	$1	$23	$55
Restructuring, impairment, and related charges, net	59	1	12	204	68	344
Non-cash charges	(58)	(1)	(9)	(14)	(16)	(98)
Cash payments	(8)	(2)	(4)	(99)	(51)	(164)
Other (2)	(5)	(1)	(3)	(2)	—	(11)
Balance, March 31, 2025 (3)	11	—	1	90	24	126
Restructuring, impairment, and related charges, net	24	—	20	43	158	245
Non-cash charges	(12)	—	(17)	8	(8)	(29)

Item 8. Financial Statements and Supplementary Data.

FAQ

What is McKesson's oncology & multispecialty — payments for restructuring?: McKesson (MCK) reported oncology & multispecialty — payments for restructuring of $0 in Q1 2026.
How has McKesson's oncology & multispecialty — payments for restructuring changed year-over-year?: McKesson's oncology & multispecialty — payments for restructuring decreased by 100.0% year-over-year, from $500K to $0.
What does oncology & multispecialty — payments for restructuring mean?: The actual cash outflow associated with executing restructuring plans, such as severance payments or lease termination fees. This measures the realized cash cost of organizational efficiency initiatives.

Ask your AI about McKesson's oncology & multispecialty — payments for restructuring.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Harbor at dusk